<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02561559</url>
  </required_header>
  <id_info>
    <org_study_id>1393</org_study_id>
    <nct_id>NCT02561559</nct_id>
  </id_info>
  <brief_title>SBRT Treatment for Lung Metastasis From Soft Tissue Sarcoma</brief_title>
  <official_title>Phase II Study to Evaluate Feasibility and Safety of Stereotactic Body Radiation Radiotherapy (SBRT) for Lung Metastases From Soft Tissue Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Clinico Humanitas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Clinico Humanitas</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study the investigators treat PM oligometastatic patients with SBRT. Our objective is
      to evaluate rate of local control of treated lesions in patients treated with Intensity
      Modulated Radiation Therapy (IMRT) using Volumetric Modulated Arc Therapy (VMAT) for lung
      metastases from STS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators started to treat PM oligometastatic patients with Stereotactic Body
      Radiotherapy.

      The investigators objective is to evaluate rate of local control of treated lesions in
      patients treated with Intensity Modulated Radiation Therapy (IMRT) using Volumetric Modulated
      Arc Therapy (VMAT) for lung metastases from soft-tissue sarcomas. Overall and disease free
      survival will be evaluated as secondary endpoints.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Local control of treated lesions</measure>
    <time_frame>12 months</time_frame>
    <description>Evaluation of proportion of patients free from progression from starting radiotherapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival of treated patients</measure>
    <time_frame>4 years</time_frame>
    <description>Evaluation of proportion of patients alive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival of treated patients</measure>
    <time_frame>4 years</time_frame>
    <description>Evaluation of proportion of patients alive and free from progression</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Metastasis From Malignant Tumor of Soft Tissues</condition>
  <arm_group>
    <arm_group_label>Lung metastasis from soft-tissue sarcoma</arm_group_label>
    <description>Lung metastases from soft-tissue sarcoma</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Lung metastasis from soft-tissue sarcoma</intervention_name>
    <description>Tretament based on Intensity Modulated Radiation Therapy (IMRT) using Volumetric Modulated Arc Therapy (VMAT)</description>
    <arm_group_label>Lung metastasis from soft-tissue sarcoma</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients affected by soft-tissue sarcomas with lung metastases unsuitable for surgery
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 anni -85 years

          -  PS according to ECOG 0-2

          -  Histopathologically confirmation of soft tissue sarcoma

          -  Metastatic lung lesion less than 4

          -  Controlled primary tumor and other metastatic lesions

          -  Metastatic lesion less than 5 such as the definition of oligometastatic patients

          -  Written informed consent

          -  Contraindication to surgical resection

          -  Estimated survival ≥ 3 months

          -  Absence of progressive disease longer than 6 months

          -  No chemotherapy was given for at least 3 months after SBRT

          -  Maximum diameter ≤ 5 cm

        Exclusion Criteria:

          -  Prior thorax radiation therapy

          -  Age &gt; 85 years

          -  PS according to ECOG &gt;2

          -  Pregnant women

          -  Maximum diameter ≥ 5.1 cm

          -  Total volume of lung lesion greater than 1/3 of the whole pulmonary parenchima
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marta Scorsetti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Clinico Humanitas</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marta Scorsetti, MD</last_name>
    <phone>+39028224</phone>
    <phone_ext>8524</phone_ext>
    <email>marta.scorsetti@cancercenter.humanitas.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pierina Navarria, MD</last_name>
    <phone>+39028224</phone>
    <phone_ext>7458</phone_ext>
    <email>piera.scorsetti@cancercenter.humanitas.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano, MI</city>
        <state>Milan</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierina Navarria, MD</last_name>
      <phone>+39028224</phone>
      <phone_ext>7458</phone_ext>
      <email>pierina.navarria@cancercenter.humanitas.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Navarria P, Ascolese AM, Cozzi L, Tomatis S, D'Agostino GR, De Rose F, De Sanctis R, Marrari A, Santoro A, Fogliata A, Cariboni U, Alloisio M, Quagliuolo V, Scorsetti M. Stereotactic body radiation therapy for lung metastases from soft tissue sarcoma. Eur J Cancer. 2015 Mar;51(5):668-74. doi: 10.1016/j.ejca.2015.01.061. Epub 2015 Feb 13.</citation>
    <PMID>25686482</PMID>
  </reference>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 25, 2015</study_first_submitted>
  <study_first_submitted_qc>September 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2015</study_first_posted>
  <last_update_submitted>February 26, 2016</last_update_submitted>
  <last_update_submitted_qc>February 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istituto Clinico Humanitas</investigator_affiliation>
    <investigator_full_name>Michele Tedeschi</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Soft Tissue Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

